Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05343533
Other study ID # IRB-19-212
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 17, 2019
Est. completion date January 1, 2022

Study information

Verified date April 2022
Source Lindenwood University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are looking to examine the impact of probiotic administration on symptoms commonly associated with depression, anxiety, stress, sleep quality, and associated emotional responses in healthy men and women.


Description:

In recent years, the presence and awareness of a connection between the intestines and the brain has expanded leading to the understanding of developed communication pathways between the nervous, endocrine, and immune systems. Intestinal bacterial flora are active contributors to this axis through cellular signaling pathways and the release of immune system components, which fundamentally impact the function and action of various physiological systems. Interest in this area evolved through the understanding that various microbiota can produce neuroactive substances and neurotransmitters involved with the endocrine and autonomic nervous system pathways. This research has expanded to state that various bacterial products can influence cognitive functions, involving types of memory and problem-solving. Recent findings have begun to report on the impact that probiotic administration may have on mood, anxiety, and depression. Finally, recent work by Marotta et al. provided some of the first preliminary evidence that probiotic use may also impact mood and sleep quality. While initial work has developed this foundation, very little controlled research is available to help understand key contributing factors. For example, many key questions remain that future research should address to help better understand any impact probiotics may have on mood, depression, and anxiety. Some of these questions include: Do all forms (genus, strain, etc.) of probiotics exert these impacts? How quickly do they exert impact? How large is the impact? Are certain aspect of affect more impacted than others? Once supplemented, how long is the residual impact (if there is any)? To help provided more guidance towards some of these basic research questions, this study is being proposed. The purpose of the study is to expand upon the previous work of Marotta et al. and determine the impact of probiotic administration on mood, depressive symptoms, anxiety, sleep quality, and other personality traits in a larger group of healthy men and women. This study will expand on the supplementation regimen and include a wider variety of hormonal assessments than what has previously been completed using this combination of probiotics.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date January 1, 2022
Est. primary completion date January 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - between the ages of 18 - 50 years - has a body mass index between 18.5 - 30 kg/m2. - Anyone with a body mass index between 30 - 32 kg/m2, but has a body composition <25% fat -for men and <35% for women will be accepted into the study - has been weight stable for the past three months (defined as less than a 5% variation in body -mass over this time) - is determined to be healthy through completion of a health history questionnaire Exclusion Criteria: - Are currently diagnosed or being treated for any cardiac, respiratory, endocrine, psychiatric, musculoskeletal, - renal, hepatic, neuromuscular or metabolic disease or disorder that in the judgement of the study participant's personal physician or research nurse that will preclude their safe participation or will contraindicate quality control over the collected data - are currently diagnosed with or are being treated for celiac disease, lactose intolerance, digestive insufficiencies or other gastrointestinal complications such as irritable bowel syndrome, ulcerative colitis, etc. - report having used anabolic steroids within the past 30 days - report have used any illicit or recreational drugs within the past 30 days - report the intake of any prescription or over-the-counter medications (i.e., antibiotics) that may impact study outcomes - report the current use of any dietary supplements known to impact digestion or sleep quality for the past 30 days - report already taking a probiotic within the past 30 days - have been actively trying to lose weight - are currently following a ketogenic or low carbohydrate diet within the past 30 days

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic
After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.

Locations

Country Name City State
United States Lindenwood University Saint Charles Missouri

Sponsors (2)

Lead Sponsor Collaborator
Lindenwood University Increnovo, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Beck Depression Index II The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression.
Total Score Levels of Depression 0-10 = These ups and downs are considered normal 11-16 = Mild mood disturbance 17-20 = Borderline clinical depression 21-30 = Moderate depression 31-40 = Severe depression over 40 = Extreme depression
6 Weeks
Primary COPE Inventory The COPE Inventory is a multidimensional coping inventory to assess the different ways in which people respond to stress. Five scales (of four items each) measure conceptually distinct aspects of problem-focused coping (active coping, planning, suppression of competing activities, restraint coping, seeking of instrumental social support); five scales measure aspects of what might be viewed as emotion-focused coping (seeking of emotional social support, positive reinterpretation, acceptance, denial, turning to religion); and three scales measuring coping responses that arguably are less useful (focus on and venting of emotions, behavioral disengagement, mental disengagement). 6 weeks
Primary Leiden Index of Depression Sensitivity - Revised The Leiden Index of Depression Sensitivity (LEIDS) measures cognitive reactivity (CR) to sadness, an aspect of cognitive vulnerability to depression, conceptually similar to rumination. A higher total score on all the subscales except acceptance and coping shows higher CR. 6 weeks
Primary Pittsburgh Sleep Quality Index A self-rated questionnaire to assess sleep quality and disturbances
19 self-reported items Minimum score: 0; Maximum score: 21 Higher scoring indicated worse sleep quality
6 weeks
Primary State-Trait Anxiety Inventory form Y1 and Y2 Measure of trait and state anxiety. All items on the scale are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety. The STAI is appropriate for those who have at least a sixth-grade reading level. 6 weeks
Primary Behavioral Avoidance/Inhibition Scale A measure of motivation to approach goal-oriented outcomes. Higher scores correspond to higher motivation to avoid goal oriented outcomes, lower scores indicate lower motivation to avoid goal-oriented outcomes. 6 weeks
Primary Bowel Health Questionnaire Measure of bowel health. Lower scores indicate lower number of GI disturbances and higher scores indicate higher number of GI disturbances 6 weeks
Secondary Hours Asleep Total hours asleep each night as obtained through a fit bit activity monitor 6 weeks
Secondary Minutes Awake Total minutes awake each night as obtained through a fit bit activity monitor 6 weeks
Secondary Number of awakenings Number of times awakened each night as obtained through a FitBit activity monitor 6 weeks
Secondary Minutes of restlessness Total minutes of restlessness each night as obtained through a FitBit activity monitor 6 weeks
Secondary Number of times Restless Number of times restless each night as obtained through a FitBit activity monitor 6 weeks
Secondary Total time Awake and Restless Total minutes of time awake and restless each night as obtained through a FitBit activity monitor 6 weeks
Secondary Total time in Bed Total time in bed each night as obtained through a FitBit activity monitor 6 weeks
Secondary Calories Burned Total KCal burned on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Steps Total number of steps on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Distance Total distance traveled each day on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Minutes Sedentary Total minutes sedentary on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Minutes Lightly Active Total minutes Lightly active on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Minutes Fairly Active Total minutes Fairly active on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Minutes Very Active Total minutes Very active on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Active Calories Total minutes of active calories expended on average each day as obtained through a FitBit activity monitor 6 weeks
Secondary Body Composition DEXA derived fat mass and fat free mass and bodyfat percentage 6 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A